Cue Biopharma (CUE) Competitors $0.74 -0.02 (-3.16%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.69%) As of 09/12/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. ALEC, PRQR, IMMP, ENGN, SOPH, OGI, TKNO, EDIT, AVTE, and ANNXShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Alector (ALEC), ProQR Therapeutics (PRQR), Prima BioMed (IMMP), enGene (ENGN), SOPHiA GENETICS (SOPH), Organigram Global (OGI), Alpha Teknova (TKNO), Editas Medicine (EDIT), Aerovate Therapeutics (AVTE), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Alector ProQR Therapeutics Prima BioMed enGene SOPHiA GENETICS Organigram Global Alpha Teknova Editas Medicine Aerovate Therapeutics Annexon Cue Biopharma (NASDAQ:CUE) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Is CUE or ALEC more profitable? Alector has a net margin of -142.10% compared to Cue Biopharma's net margin of -469.35%. Alector's return on equity of -112.06% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-469.35% -230.13% -111.16% Alector -142.10%-112.06%-26.37% Do institutionals & insiders believe in CUE or ALEC? 35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by company insiders. Comparatively, 9.7% of Alector shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CUE or ALEC? Cue Biopharma has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Do analysts recommend CUE or ALEC? Alector has a consensus price target of $4.17, indicating a potential upside of 51.52%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29 Which has stronger valuation & earnings, CUE or ALEC? Cue Biopharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$8.29M6.88-$40.67M-$0.56-1.32Alector$100.56M2.77-$119.05M-$1.16-2.37 Does the media prefer CUE or ALEC? In the previous week, Alector had 4 more articles in the media than Cue Biopharma. MarketBeat recorded 6 mentions for Alector and 2 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.28 beat Alector's score of 1.23 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlector beats Cue Biopharma on 9 of the 16 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.84M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-1.3221.1774.5225.93Price / Sales6.88437.97517.44183.79Price / CashN/A46.6837.5660.44Price / Book2.659.6112.166.29Net Income-$40.67M-$53.29M$3.28B$270.77M7 Day Performance-4.94%0.28%0.87%3.88%1 Month Performance-8.49%5.73%4.96%4.88%1 Year Performance25.89%10.52%60.75%26.01% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma2.5295 of 5 stars$0.74-3.2%N/A+27.8%$58.84M$8.29M-1.3260Positive NewsHigh Trading VolumeALECAlector3.9587 of 5 stars$2.35-1.7%$4.17+77.3%-51.0%$237.85M$100.56M-2.03270Positive NewsAnalyst UpgradePRQRProQR Therapeutics2.5975 of 5 stars$2.25+2.7%$8.00+255.6%+18.4%$236.73M$20.46M-4.89180News CoveragePositive NewsShort Interest ↑IMMPPrima BioMed1.452 of 5 stars$1.61-3.0%$7.00+334.8%-37.6%$236.33M$5.14M0.002,021News CoverageENGNenGene2.6545 of 5 stars$4.62-2.7%$23.29+404.0%-14.1%$236.11MN/A-2.8031Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionSOPHSOPHiA GENETICS2.0196 of 5 stars$3.46+4.5%$8.00+131.2%-20.0%$233.82M$65.17M-7.86520Gap DownOGIOrganigram Global1.1117 of 5 stars$1.73flatN/A-9.8%$231.91M$117.47M34.61860TKNOAlpha Teknova2.8158 of 5 stars$4.32+0.2%$10.00+131.5%-2.4%$231.19M$37.74M-10.29240Positive NewsEDITEditas Medicine4.3415 of 5 stars$2.57-3.0%$5.10+98.4%-28.3%$231.10M$32.31M-0.90230AVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.2%$228.98MN/A-2.6420Positive NewsHigh Trading VolumeANNXAnnexon2.4385 of 5 stars$2.06-2.8%$12.50+506.8%-64.0%$226.37MN/A-1.6060Positive News Related Companies and Tools Related Companies Alector Alternatives ProQR Therapeutics Alternatives Prima BioMed Alternatives enGene Alternatives SOPHiA GENETICS Alternatives Organigram Global Alternatives Alpha Teknova Alternatives Editas Medicine Alternatives Aerovate Therapeutics Alternatives Annexon Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
